Loading
Tiredness that rest does not fix is one of the commonest effects of cancer and its treatment, for months or years. Your team should ask about it and look for treatable causes such as anaemia, low thyroid, pain, poor sleep, low mood or a medicine. What helps most is exercise suited to you, cognitive behavioural therapy and mindfulness. Modafinil is not recommended, nor methylphenidate routinely.
The ASCO-SIO guideline update (2024) covers adults from diagnosis onward and sorts recommendations by phase. During treatment, clinicians should recommend exercise (aerobic, resistance or both), CBT, mindfulness-based programmes and tai chi or qigong (each moderate evidence, strong recommendation); psychoeducation and American ginseng 2,000 mg daily may be recommended (conditional). After treatment, exercise, CBT and mindfulness-based programmes are strong recommendations, and yoga, acupressure and moxibustion conditional. In advanced cancer or at the end of life, CBT and corticosteroids may be offered (low evidence, conditional). In every phase, wakefulness agents (modafinil, armodafinil) should not be recommended, and psychostimulants (methylphenidate) should not be used routinely; during treatment, L-carnitine and antidepressants such as paroxetine are also recommended against.
Screening and assessment were not re-examined in 2024; the panel referred readers to the 2014 ASCO adaptation, which recommends that everyone be evaluated for fatigue after primary treatment and that those with moderate to severe fatigue have a comprehensive assessment with medical and treatable contributing factors addressed. The APTA guideline (2022) grades the tools: the EORTC QLQ-C30 is the only screening tool graded A, and the Piper Fatigue Scale-Revised, FACIT-Fatigue and PROMIS Fatigue short forms are graded A for fuller assessment. The ESMO 2020 guideline could not be read.
Why: Fatigue is often thought to be unavoidable and goes unreported; asking routinely finds the people who could be helped.
“It is recommended that all patients with cancer be evaluated for the presence of fatigue after completion of primary treatment and be offered specific information and strategies for fatigue management.”
Why: A short standard questionnaire catches tiredness that a general question misses, and shows change over time.
“Only 1 screening tool rises to the level of grade A evidence for screening CRF. The EORTC-QLQ-C30 is a general symptom inventory that can be used to screen for fatigue and other problems those with cancer may have. The MDASI, also a general symptom inventory in which the individual with cancer assesses their present symptom burden, is graded B.”
Academy of Oncologic Physical Therapy of APTA, Physical Therapy 2022 · A (EORTC QLQ-C30); B (MDASI)
Why: Several of these can be corrected directly, and fatigue rarely improves while they are untreated.
“patients experiencing fatigue should also be evaluated and treated for contributing comorbid conditions that commonly cluster with fatigue, including pain, depression, anxiety, and sleep disturbance, as well as nutritional deficit, activity level, anemia, medication adverse effects.”
Why: Fatigue can be the first sign of a hormone gland being damaged by immunotherapy, which needs its own treatment.
“Fatigue can also be a symptom of other forms of immunotherapy toxicity, including adrenal insufficiency, hypothyroidism, hypophysitis, hepatitis, renal insufficiency, pneumonitis, neurologic toxicities, and anemia.”
Why: Exercise has the most consistent evidence of any treatment for cancer-related fatigue.
“1.1. Clinicians should recommend exercise (aerobic, resistance, or a combination) to reduce the severity of fatigue during cancer treatment. Exercise should be tailored according to the individual patient’s abilities and may be either supervised or unsupervised Moderate Strong”
ASCO and SIO, Journal of Clinical Oncology 2024 · Evidence quality moderate; recommendation strong
Why: Both reduce fatigue in randomised trials, and after treatment they have worked for people with moderate to severe fatigue.
“2.2. Clinicians should recommend cognitive behavioral therapy (CBT) to manage symptoms of cancer-related fatigue in adults who have completed cancer treatment. CBT may be delivered in person or via a web-based program Moderate Strong”
ASCO and SIO, Journal of Clinical Oncology 2024 · Evidence quality moderate; recommendation strong
Why: These gentle movement practices reduced fatigue in trials of people on treatment.
“1.4. Clinicians should recommend tai chi or qigong, practiced at a low to moderate intensity, to reduce the severity of cancer-related fatigue in adults undergoing cancer treatment Moderate Strong”
ASCO and SIO, Journal of Clinical Oncology 2024 · Evidence quality moderate; recommendation strong
Why: Trials have not shown these drugs help cancer-related fatigue enough to outweigh their side effects.
“1.7. Clinicians should not recommend wakefulness agents, such as modafinil or armodafinil, to manage symptoms of cancer-related fatigue in adults undergoing cancer treatment Moderate Strong”
ASCO and SIO, Journal of Clinical Oncology 2024 · Evidence quality moderate; recommendation strong (against), during treatment
Why: A short course of a steroid can lift fatigue near the end of life, but its side effects build up with time.
“3.2. Clinicians may recommend corticosteroids to manage symptoms of cancer-related fatigue in patients at the end of life where no contraindications exist. The risk-benefit ratio of corticosteroid use should be assessed over time Low Conditional”
ASCO and SIO, Journal of Clinical Oncology 2024 · Evidence quality low; recommendation conditional
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
ASCO-SIO 2024 is the most recent graded guideline read, and MASCC endorsed it in 2026 (endorsement not read). It puts exercise, CBT and mindfulness-based programmes first in every phase before and after the end of treatment (moderate evidence, strong recommendation), adds tai chi or qigong during treatment, and recommends against wakefulness agents and routine psychostimulants. For screening and choosing a tool, the 2014 ASCO adaptation (screen everyone; assess and correct causes in moderate to severe fatigue) and the APTA 2022 tool grades are the sources read. Where these differ from ESMO 2020 cannot be said, because the ESMO guideline could not be read.
ASCO and SIO, Journal of Clinical Oncology 2024 · ASCO, Journal of Clinical Oncology 2014 · Academy of Oncologic Physical Therapy of APTA, Physical Therapy 2022 · ESMO, Annals of Oncology 2020 · MASCC, Supportive Care in Cancer 2026
Where it differs: Adds a supplement, Panax quinquefolius 2,000 mg a day, for fatigue during treatment.
Evidence: ASCO-SIO 2024 grades the evidence low and the recommendation conditional; after treatment it found the evidence on ginseng insufficient to recommend for or against. It suggests twice-daily dosing, morning and before noon, to avoid disturbing sleep. Supplements can interact with cancer drugs, so a pharmacist should check.
Where it differs: Mind-body or traditional Chinese medicine approaches offered after treatment instead of or alongside exercise and CBT.
Evidence: Each conditional on low-quality evidence in ASCO-SIO 2024 after treatment (yoga especially in women with breast cancer). During treatment, the panel found the evidence on yoga and acupressure insufficient.
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Mindfulness-based programmes reduce fatigue after treatment “2.3. Clinicians should recommend mindfulness-based programs to reduce the severity of fatigue in adults who have completed cancer treatment.” | Moderate; Strong | ASCO and SIO, Journal of Clinical Oncology 2024 |
| Psychostimulants are not recommended routinely during treatment “1.9. Clinicians should not routinely recommend psychostimulants, such as methylphenidate, to manage symptoms of cancer-related fatigue in adults undergoing cancer treatment Moderate Conditional” | Moderate; Conditional (against) | ASCO and SIO, Journal of Clinical Oncology 2024 |
| Antidepressants are not recommended for fatigue during treatment “1.10. Clinicians should not recommend antidepressants, such as paroxetine, to manage symptoms of cancer-related fatigue in adults undergoing cancer treatment Moderate Conditional” | Moderate; Conditional (against) | ASCO and SIO, Journal of Clinical Oncology 2024 |
| Exercise in advanced cancer or at the end of life “There is insufficient evidence to make recommendations for or against collaborative care intervention, exercise, melatonin, or protocolized patient-tailored treatment to manage symptoms of cancer-related fatigue among adults with advanced cancer or at the end of life” | Insufficient; no recommendation | ASCO and SIO, Journal of Clinical Oncology 2024 |
| Multidimensional assessment tools “Grade A scales of the PFS-R, the FACIT–Fatigue, and the PROMIS Fatigue–Short Forms.” | A | Academy of Oncologic Physical Therapy of APTA, Physical Therapy 2022 |
Shares Cognitive behavioural therapy for fatigue and distress, Exercise & lifestyle oncology, European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO) and the tags protocol, supportive-care, survivorship.
Shares Mindfulness-based stress reduction and cognitive therapy, Cancer-related fatigue (tiredness), Exercise & lifestyle oncology, European Society for Medical Oncology (ESMO) and the tags protocol, supportive-care.
Shares Mindfulness-based stress reduction and cognitive therapy, Cognitive behavioural therapy for fatigue and distress, American Society of Clinical Oncology (ASCO) and the tags protocol, supportive-care.
Shares Multinational Association of Supportive Care in Cancer, European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Dexamethasone and the tags protocol, supportive-care.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO) and the tags protocol, survivorship.
Shares Multinational Association of Supportive Care in Cancer, European Society for Medical Oncology (ESMO) and the tags protocol, supportive-care.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO) and the tags protocol, supportive-care.
Shares Multinational Association of Supportive Care in Cancer, American Society of Clinical Oncology (ASCO) and the tags protocol, supportive-care.